Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study
Authors:
- Mohammad MovahediMMMohammad Movahedi
- D. Timothy BishopDBD. Timothy Bishop
- Finlay MacraeFMFinlay Macrae
- Jukka-Pekka MecklinJMJukka-Pekka Mecklin
- Gabriela MoesleinGMGabriela Moeslein
- Sylviane OlschwangSOSylviane Olschwang
- Diana EcclesDEDiana Eccles
- D. Gareth EvansD. Gareth Evans
- Eamonn R. MaherEMEamonn R. Maher
- Lucio BertarioLBLucio Bertario
- Marie-Luise BisgaardMBMarie-Luise Bisgaard
- Malcolm G. DunlopMDMalcolm G. Dunlop
- 1 November 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (31) , 3591-3597
Abstract
Purpose: In the general population, increased adiposity is a significant risk factor for colorectal cancer (CRC), but whether obesity has similar effects in those with hereditary CRC is uncertain. This prospective study investigated the association between body mass index and cancer risk in patients with Lynch syndrome (LS). Patients and Methods: Participants with LS were recruited to the CAPP2 study, in which they were randomly assigned to receive aspirin 600 mg per day or aspirin placebo, plus resistant starch 30 g per day or starch placebo (2 × 2 factorial design). Mean intervention period was 25.0 months, and mean follow-up was 55.7 months. Results: During follow-up, 55 of 937 participants developed CRC. For obese participants, CRC risk was 2.41× (95% CI, 1.22 to 4.85) greater than for underweight and normal-weight participants (reference group), and CRC risk increased by 7% for each 1-kg/m2 increase in body mass index. The risk of all LS-related cancers in obese people was 1.77× (95% CI, 1.06 to 2.96; P = .03) greater than for the reference group. In subgroup analysis, obesity was associated with 3.72× (95% CI, 1.41 to 9.81) greater CRC risk in patients with LS with MLH1 mutation, but no excess risk was observed in those with MSH2 or MSH6 mutation (P = .5). The obesity-related excess CRC risk was confined to those randomly assigned to the aspirin placebo group (adjusted hazard ratio, 2.75; 95% CI, 1.12 to 6.79; P = .03). Conclusion: Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin. Such patients are likely to benefit from obesity prevention and/or regular aspirin.Keywords
This publication has 25 references indexed in Scilit:
- Prospective Investigation of Body Mass Index, Colorectal Adenoma, and Colorectal Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialJournal of Clinical Oncology, 2013
- Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective StudiesPLOS ONE, 2013
- Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesisObesity Reviews, 2012
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2011
- Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genesBritish Journal of Cancer, 2011
- Intestinal Inflammation and CancerGastroenterology, 2011
- Body Mass Index Increases Risk of Colorectal Adenomas in Men With Lynch Syndrome: The GEOLynch Cohort StudyJournal of Clinical Oncology, 2010
- Excess Body Weight and Colorectal Cancer Risk in Canada: Associations in Subgroups of Clinically Defined Familial Risk of CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite InstabilityJNCI: Journal of the National Cancer Institute, 2004
- The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)Diseases of the Colon & Rectum, 1991